中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (6) :441-445    DOI: 10.11669/cpj.2013.06.011
��Դ����� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
������ͪ�����򲡴���������ŵ��ױ���Ӱ��
������,����ƽ*
�ϻ���ѧ�����ڶ�ҽԺ�ڷ��ڿ�,���� ���� 421001
ZHANG Shi-jing,WANG Jian-ping*
Department of Endocrinology,the Second Affiliated Hospital of Nanhua University,Heng Yang 421001,China

Download: PDF (984KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �۲�������ͪ�����򲡴�������֯���ŵ��ױ���Ӱ�졣���� SD���������Ϊ�������������ģ�顣�����������յ����򲡴�����ģ�ɹ��Ĵ��������Ϊ�����顢������ͪ3,15 mg·kg-1·d-1�顣8��ĩ�����24 h��΢���׵��ס�Ѫ��,Ѫ������HEȾɫ�۲�����֯��̬,������֯��ѧ������ת¼-�ۺ�ø����Ӧ���ֱ���������֯���ŵ��׼����ŵ���mRNA�ı���� ������ͪ3 mg·kg-1·d-1�顢������ͪ15 mg·kg-1·d-1��Ѫ������΢���׵��ס�������/�������������������½���P<0.05������������Ƚ�,������ͪ15 mg·kg-1·d-1��Ѫ�����Խ��ͣ�P<0.05��,������ͪ3 mg·kg-1·d-1��Ѫ�������Ը���,������ͳ��ѧ���壨P>0.05��������������֯���ŵ��׼����ŵ���mRNA���ˮƽ�������������������ߣ�P<0.05����������ͪ3,15 mg·kg-1·d-1������֯���ŵ��ס����ŵ���mRNA���ˮƽ��������������½���P<0.05�������� ���򲡴�������֯���ŵ��ױ������,��ʾ���ŵ��׿��ܲ����������ಡ��ķ������̡�������ͪ��Ԥ���Լ������򲡴�����΢���׵���,�������б������á�������ͪ������ı������ò��ֿ�����������ͪ����������ŵ��׵ı���йء�
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
������
����ƽ*
�ؼ����� ������ͪ    ��������    ���ŵ���    ��֢     
Abstract�� Objective To investigate the effect of pioglitazone on renal osteopontin expression in diabetic rats. METHODS Sprague Dawlry rats were randomly divided into the normal control group and the model group. Diabetes was induced by streptozotocin (STZ) in the model group rats. After diabetes was confirmed,diabetic rats were assigned randomly into three subgroups: the diabetic rats without treatment,3 and 15 mg·kg-1·d-1 pioglitazone treated diabetic rats. At the end of the 8th week,24 h urine samples were collected to examine microalbuminuria (mAlb). At the same time,blood glucose levels and serum creatinine (Scr) were measured. Stained kidney sections were observed under light microscope. The expressions of OPN protein and OPN mRNA were detected by immunohistochemistry and reverse transcription-polymerase chain reaction��RT-PCR��,respectively. RESULTS Treatment with 3 and 15 mg·kg-1·d-1 pioglitazone could decrease Scr,mAlb and RKW in diabetic rats. Compared with diabetic rats,blood glucose level was lower in diabetic rats treated with 15 mg·kg-1·d-1 pioglitazone�� however,no significant change was observed at the 3 mg·kg-1·d-1 dose. Compared with normal control rats,the OPN protein and mRNA expressions of the whole nephritic kidney in diabetic rats were upregulated (P<0.05). After treatment with 3 and 15 mg·kg-1·d-1 pioglitazone,the expressions of OPN protein and mRNA reduced compared with diabetic rats (P<0.05). CONCLUSION The OPN expression in renal tissues is increased in diabetic rats,suggesting that OPN has emerged as a potential key pathophysiologic contributor in diabetic nephropathy (DN). Pioglitazone can reduce microalbuminuria in diabetic rats. The renal protective effect of pioglitazone in DN may involve the suppression of increased OPN.
Keywords�� pioglitazone ,   diabetic nephropathy ,   osteopontin ,   inflammation     
�ո�����: 2012-04-26;
ͨѶ���� ����ƽ,��,������,˶ʿ����ʦ �о������ڷ��� Tel/Fax����0734��8899675 E-mail��wangjpppp@yahoo.com.cn������ͪ�����򲡴���������ŵ��ױ���Ӱ��������     Email: wangjpppp@yahoo.com.cn
���߼��: ������,Ů,˶ʿ,סԺҽʦ �о������ڷ��� ͨѶ���ߣ�����ƽ,��,������,˶ʿ����ʦ �о������ڷ��� Tel/Fax����0734��8899675 E-mail��wangjpppp@yahoo.com.cn
���ñ���:   
������, ����ƽ* .������ͪ�����򲡴���������ŵ��ױ���Ӱ��[J]  �й�ҩѧ��־, 2013,V48(6): 441-445
ZHANG Shi-Jing, WANG Jian-Ping-* .Effect of Pioglitazone on Renal Osteopontin Expression in Diabetic Rats[J]  Chinese Pharmaceutical Journal, 2013,V48(6): 441-445
��
[1] KO G J,KANG Y S,HAN S Y,et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant,2008,23(9):2750-2760.
[2] KLINGEL K,KANDOLF R. Osteopontin: A biomarker to predict the outcome of inflammatory heart disease. Semin Thromb Hemost,2010,36(2):195-202.
[3] MORIMOTO J,KON S,MATSUI Y,et al. Osteopontin as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets,2010,11(4):494-505.
[4] RIVERO A,MORA C,MUROS M,et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci,2009,116��6��:479-492.
[5] LORENZEN J,KR MER R,KLIEM V,et al. Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest,2010,40(4):294-300.
[6] SRINIVASAN K,PATOLE P S,KAUL C L,et al.Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol,2004,26��5��: 327-333.
[7] MOHAPATRA J,SHARMA M,SINGH S,et al. Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice. Pharmacology,2009,84(4):203-210.
[8] ONOZAKI A,MIDORIKAWA S,SANADA H,et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF:Inhibitory effects of thiazolidinedione. Biochem Biophys Res Commun,2004,317��1��:24-29.
[9] CAO Y P,GAO F,HAO J,et al. Expression and implication of osteopontin in renal cortex of diabetic rats. Chin Crit Care Med(�й�Σ�ز�����ҽѧ),2008,20(5):287-290.
[10] LORENZEN J,SHAH R,BISER A,et al. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol,2008,19(5):884-890.
[11] NICHOLAS S B,LIU J,KIM J,et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int,2010,77(7):588-600.
[12] SHINOHARA M L,LU L,BU J,et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol,2006,7��5��:498-506.
[1] ½���� ���� .�鵰��ȥ������ø���Ƽ��ڷ�����������о���չ[J]. �й�ҩѧ��־, 2012,47(5): 321-324
[2] �����������ޣ��˾��ϣ���С����������.��ܺຶ������������յ�2�����򲡴����������������ü�����[J]. �й�ҩѧ��־, 2012,47(22): 1807-1812
[3] �Żݣ�����������갺������ѧƽ��������.����Է�������͸�������Ʊ���������������о���չ[J]. �й�ҩѧ��־, 2012,47(13): 1022-1024
[4] ������ ������ ������ ����.ά����D�����������ǻ�����ҩ�������о���չ[J]. �й�ҩѧ��־, 2011,46(22): 1700-1703
[5] ������ ������ ����ʤ ������ ������.����ض����򲡴�������ѪС�巴Ӧ����1����������õ��о�[J]. �й�ҩѧ��־, 2011,46(17): 1326-1329
[6] �Ҵ��� ���� ���� ��С�� �¼Ѻ� ̷������HT.ϸ����Ĥ���ںϵ���PEP1-vMIP-��ٽ�Ѫ�������о�[J]. �й�ҩѧ��־, 2011,46(11): 809-813
[7] ��ѩ�� ���� �Ű��� ̷��.Ѫ֬����ѹ�����ɵ����ļ��ع��ı�������[J]. �й�ҩѧ��־, 2011,46(1): 31-34
[8] ����Ц Īѩ÷ ���� ����Ӣ �Ź�.ӫ�ⶨ��PCR���о����鲡������ϸ����֢����������ҩ���⿹HIV-1������[J]. �й�ҩѧ��־, 2010,45(11): 814-817
[9] ���� ��ҫ��.���������򲡴�������������Y����Y1��Y2�������Ӱ��[J]. �й�ҩѧ��־, 2010,45(10): 747-750
[10] ��Զ ���� ���� ���� ������ ��ܲ��.������ͪ�������������ͼ����߾�����Ӳ����Ӱ��[J]. �й�ҩѧ��־, 2010,45(10): 764-767
[11] �ɽ��� ;Ҷ���� . ������ͪ�ԷǾƾ���֬���Ըβ�����Ѫ���ֿ������ȵ��صֿ���Ӱ��[J]. �й�ҩѧ��־, 2009,44(24): 1900-1903
[12] κ��;κΰ.���ζ��նԴ���ԭ�Թؽ��׵���������[J]. �й�ҩѧ��־, 2008,43(10): 746-750
[13] �����;����.���Ծ����ڶ����´���ȫ����֢��Ӧ�ۺ�����Ӱ��[J]. �й�ҩѧ��־, 2006,41(15): 1142-1144
[14] ������;������.��֢�Գ����Ľ᳦���������ͽ᳦��λ��ҩ[J]. �й�ҩѧ��־, 2006,41(02): 86-90
[15] ���;�ſ���;����Ң;����ǫ.��޼«����PPAR-�ü������õ��о�[J]. �й�ҩѧ��־, 2005,39(12): 905-907
Copyright 2010 by �й�ҩѧ��־